Linked Life Data

8342072

Source:http://linkedlifedata.com/resource/pubmed/id/8342072

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8342072rdf:typepubmed:Citationlld:pubmed
pubmed-article:8342072lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8342072lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:8342072lifeskim:mentionsumls-concept:C0149615lld:lifeskim
pubmed-article:8342072lifeskim:mentionsumls-concept:C0006463lld:lifeskim
pubmed-article:8342072lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:8342072lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:8342072lifeskim:mentionsumls-concept:C1519814lld:lifeskim
pubmed-article:8342072pubmed:issue4 Suppl 4lld:pubmed
pubmed-article:8342072pubmed:dateCreated1993-9-1lld:pubmed
pubmed-article:8342072pubmed:abstractTextAllogeneic bone marrow transplantation (BMT) has been shown to result in long-term disease-free survival in patients with leukemia. However, the utility of this treatment approach is limited by treatment-related morbidity and mortality. We present an update of a study in which a BMT preparative regimen consisting of a 4-day course of busulfan and a 2-day course of cyclophosphamide (BuCy2) was used in patients with chronic myelogenous leukemia. Patient survival depended on disease stage, with a 58% survival rate for patients in first chronic phase, 41% for those in accelerated phase, and 25% for those in the blast transformation stage. There was a significant difference in patient survival between those who received transplants within 1 year of diagnosis and those who received transplants more than 1 year after diagnosis (70% v 40%). This difference appeared to be due to the extent of previous exposure to busulfan. The overall mortality rate in this study was 46%. We conclude that the BuCy2 preparative regimen is similar in effectiveness to regimens that include total body irradiation and results in comparable levels of transplant-related mortality. Our results strongly indicate that patients with chronic myelogenous leukemia who receive BMT within the first year after diagnosis have a significantly better clinical outcome than those who receive BMT later in the course of the disease.lld:pubmed
pubmed-article:8342072pubmed:languageenglld:pubmed
pubmed-article:8342072pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8342072pubmed:citationSubsetIMlld:pubmed
pubmed-article:8342072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8342072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8342072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8342072pubmed:statusMEDLINElld:pubmed
pubmed-article:8342072pubmed:monthAuglld:pubmed
pubmed-article:8342072pubmed:issn0093-7754lld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:SvábZZlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:BrodskyIIlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:AtkinsonKKlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:ConcannonA...lld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:BiggsJ CJClld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:DownsKKlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:AvalosB RBRlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:CrilleyPPlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:DoddsAAlld:pubmed
pubmed-article:8342072pubmed:authorpubmed-author:TutschkaPPlld:pubmed
pubmed-article:8342072pubmed:issnTypePrintlld:pubmed
pubmed-article:8342072pubmed:volume20lld:pubmed
pubmed-article:8342072pubmed:ownerNLMlld:pubmed
pubmed-article:8342072pubmed:authorsCompleteNlld:pubmed
pubmed-article:8342072pubmed:pagination27-31; quiz 32lld:pubmed
pubmed-article:8342072pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:meshHeadingpubmed-meshheading:8342072-...lld:pubmed
pubmed-article:8342072pubmed:year1993lld:pubmed
pubmed-article:8342072pubmed:articleTitleTreatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.lld:pubmed
pubmed-article:8342072pubmed:affiliationDepartment of Neoplastic Diseases, Hahnemann University, Philadelphia, PA 19102.lld:pubmed
pubmed-article:8342072pubmed:publicationTypeJournal Articlelld:pubmed